Citicoline induces angiogenesis improving survival of vascular/human brain microvessel endothelial cells through pathways involving ERK1/2 and insulin receptor substrate-1

Vascular Cell

Volumn 4, Issue , 2012, Pages

  Krupinski, Jerzy ^a,b,c   Abudawood, Manal ^c   Matou Nasri, Sabine ^c   Al Baradie, Raid ^d   Petcu, Eugen Bogdan ^e   Justicia, Carlos ^f   Planas, Anna ^f   Liu, Donghui ^c   Rovira, Norma ^a   Grau Slevin, Marta ^g   Secades, Julio ^h   Slevin, Mark ^c,g  

^a HOSPITAL UNIVERSITARI DE BELLVITGE   (Spain)

^b UNIVERSITY OF MANCHESTER   (United Kingdom)

^c MANCHESTER METROPOLITAN UNIVERSITY   (United Kingdom)

^d MAJMAAH UNIVERSITY   (Saudi Arabia)

^e GRIFFITH UNIVERSITY   (Australia)

^f INSTITUT D INVESTIGACIONS BIOMÈDIQUES AUGUST PI I SUNYER IDIBAPS   (Spain)

^g HOSPITAL DE LA SANTA CREU I SANT PAU   (Spain)

^h Ferrer Grupo   (Spain)

Author keywords

Angiogenesis; Apoptosis; Citicoline; IRS 1; Ischaemia; Stroke

Indexed keywords

CALCIUM IONOPHORE; CITICOLINE; ENDOGLIN; INSULIN RECEPTOR SUBSTRATE 1; MATRIGEL; MITOGEN ACTIVATED PROTEIN KINASE 1; MITOGEN ACTIVATED PROTEIN KINASE 3; SMALL INTERFERING RNA; STAUROSPORINE;

ANGIOGENESIS; ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; BRAIN ISCHEMIA; CELL DIFFERENTIATION; CELL MIGRATION; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; HUMAN; HUMAN CELL; IMMUNOHISTOCHEMISTRY; IN VITRO STUDY; IN VIVO STUDY; MALE; MICROVASCULATURE; MIDDLE CEREBRAL ARTERY OCCLUSION; NONHUMAN; PILOT STUDY; PRIORITY JOURNAL; PROTEIN EXPRESSION; RAT; VASCULAR ENDOTHELIUM; WESTERN BLOTTING; WOUND HEALING;

EID: 84873022304     PISSN: None     EISSN: 2045824X     Source Type: Journal    
DOI: 10.1186/2045-824X-4-20     Document Type: Article

References (24)

1. Probably role of citicoline in stroke rehabilitation: review of the literature. Secades JJ, Rev Neurol 2012 54 3 173 179 22278894
2. Clinical use of cholinomimetic agents: a review. Blount PJ, Nguyen CD, McDeavitt JT, J Head Trauma Rehabil 2002 17 314 321 10.1097/00001199-200208000- 00005 12106000 (Pubitemid 34809596)
3. A chronic treatmente with CDP-choline improves functional recovery and increases neuronal plasticity after experimental stroke. Hurtado O, Cárdenas A, Pradillo JM, Morales JR, Ortego F, Sobrino T, et al. Neurobiol Dis 2007 26 105 111 10.1016/j.nbd.2006.12.005 17234423 (Pubitemid 46436490)
4. Citicoline preclinical and clinical update 2009-2010. Davalos A, Secades J, Stroke 2011 42 36 S39 10.1161/STROKEAHA.110.605568 21164116
5. Citicoline protects against cognitive impairment in a rat model of chronic cerebral hypoperfusion. Lee HJ, Kang JS, Kim YI, J Clin Neurol 2009 5 33 38 10.3988/jcn.2009.5.1.33 19513332
6. Selecting the optimal dose of citicoline treatment in animal models of focal cerebral ischaemia through a meta-analysis. Giralt D, Garcia-Bonilla L, Campos M, Sosti V, Rosell A, Montaner J, Cerebrovasc Dis 2010 29 165
7. Citicoline: updata on a promising and widely available agent for neuroprotection and neurorepair. Saver JL, Rev Neurol Dis 2008 5 167 177 19122569
8. CDP-choline reduces pro-caspase and cleaved caspase-3 expression, nuclear DNA fragmentation, and specific PARP-cleaved products of caspase activation following middle cerebral artery occlusion in the rat. Krupinski J, Ferrer I, Barrachina M, Secades JJ, Mercadal J, Lozano R, Neuropharmacology 2002 42 846 854 10.1016/S0028-3908(02)00032-1 12015211 (Pubitemid 34518284)
9. Blood-brain barrier-specific properties of a human adult brain endothelial cell line. Weksler BB, Subileau EA, Perriere N, Charneau P, Holloway K, Leveque M, et al. FASEB J 2005 19 1872 1874 16141364 (Pubitemid 41598779)
10. Modified C-reactive protein is expressed by stroke neovessels and is a potent activator of angiogenesis in vitro. Slevin M, Matou-Nasri S, Turu M, Luque A, Rovira N, Badimon L, et al. Brain Pathol 2010 20 151 165 10.1111/j.1750-3639.2008.00256.x 19170684
11. Reversible middle cerebral artery occlusion without craniectomy in rats. Longa EZ, Weinstein PR, Carlson S, Cummins R, Stroke 1989 20 84 91 10.1161/01.STR.20.1.84 2643202 (Pubitemid 19040218)
12. Potent in vivo antiangiogenic effects of GS-101 (5′- TATCCGGAGGGCTCGCCATGCTGCT-3′) an antisense oligonucleotide preventing the expression of insulin receptor substrate-1. Al-Mahmood S, Colin S, Farhat N, Thorin E, Steverlynck C, Chemtob S, J Pharmacol Exp Ther 2009 329 496 504 10.1124/jpet.108.147496 19208899
13. CDP-choline protects motor neurons against apoptotic changes in a model of chronic glutamate excitotoxicity in vitro. Matyja E, Taraszewska A, Naganska E, Grieb P, Rafalowska J, Folia Neuropathol 2008 46 139 148 18587708
14. Effects of citicoline used alone and in combination with mild hypothermia on apoptosis induced by focal cerebral ischaemia in rats. Sahin S, Alkran T, Temel SG, Tureyen K, Tolunay S, Korfali E, J Clin Neurosci 2010 17 227 231 10.1016/j.jocn.2009.05.016 20036128
15. Neuroprotective effect of citicoline on retinal cell damage induced by kainic acid in rats. Han YS, Chung IY, Park JM, Yu JM, Korean J Ophthalmol 2005 19 219 226 10.3341/kjo.2005.19.3.219 16209285
16. Molecular mechanisms involved in farnesol-induced apoptosis. Joo JH, Jetten AM, Cancer Lett 2010 287 123 135 10.1016/j.canlet.2009.05.015 19520495
17. Competetive inhibition of choline phosphotransferase by geranylgeraniol and farnesol inhibits phosphatidylcholine synthesis and induces apoptosis in human lung adenocarcinoma A549 cells. Miquel K, Pradines A, Terce F, Selmi S, Favre G, J Biol Chem 1998 273 26179 26186 10.1074/jbc.273.40.26179 9748300 (Pubitemid 28475855)
18. Apoptotic phosphorylation of histone H2B by mammalian sterile twenty kinase. Cheung WL, Ajiro K, Samejima K, Kloc M, Cheung P, Mizzen CA, et al. Cell 2003 113 507 517 10.1016/S0092-8674(03)00355-6 12757711 (Pubitemid 36603322)
19. Pathophysiology of acute ischaemic stroke: an analysis of common signalling mechanisms and identification of new molecular targets. Mitsios N, Gaffney J, Kumar P, Krupinski J, Kumar S, Slevin M, Pathobiol 2006 73 159 175 10.1159/000096017 (Pubitemid 44808076)
20. Can angiogenesis be exploited to improve stroke outcome? Mechanisms and therapeutic potential. Slevin M, Kumar P, Gaffney J, Kumar S, Krupinski J, Clin Sci 2006 111 171 183 10.1042/CS20060049 16901264 (Pubitemid 44352189)
21. Down-regulation of IRS-1 expression causes inhibition of corneal angiogenesis. Andrieu-Soler C, Berdugo M, Doat M, Courtois Y, BenEzra D, Behar-Cohen E, Invest Ophthalmol Vis Sci 2005 46 4072 4078 10.1167/iovs.05-0105 16249482 (Pubitemid 44264606)
22. Tolerability and safety of GS-101 eye drops, an antisense oligonucleotide to insulin receptor substrate-1: a first in man phase 1 investigation. Kain H, Goldblum D, Geudelin B, Thorin E, Beglinger C, Br J Clin Pharmacol 2009 68 169 173 10.1111/j.1365-2125.2009.03450.x 19694734
23. Combination treatment with HER-2 and VEGF peptide mimics induces potent anti-tumour and anti-angiogenic responses in vitro and in vivo. Foy KC, Liu Z, Phillips G, Miller M, Kaumaya PT, J Biol Chem 2011 286 13626 13637 10.1074/jbc.M110.216820 21325276
24. HER2 signaling modulates the equilibrium between pro-and antiangiogenic factors via distinct pathways: implications for HER2 -targeted antibody therapy. Wen XF, Yang G, Mao W, Thornton A, Liu J, Bast RC Jr, Le XF, Oncogene 2006 25 6986 6996 10.1038/sj.onc.1209685 16715132 (Pubitemid 44684839)